Texas Heart Institute and BiVACOR achieve milestone with total artificial heart implantation

FHS
July 25, 2024
4:31 pm

The Texas Heart Institute (THI) and BiVACOR, a clinical-stage medical device company, announced today the successful first-in-human implantation of the BiVACOR Total Artificial Heart (TAH) as part of the U.S. Food and Drug Administration (FDA) Early Feasibility Study (EFS) on July 9, 2024.

Califf backs increased LDT oversight despite industry opposition

Listen to the article 5 min This audio is auto-generated. Please let us know if you have feedback. Dive Brief: Food and Drug Administration Commissioner

February 1, 2024

Automated system enhances stroke rehabilitation using robots

The increasing number of strokes and subsequent rehabilitation has highlighted the growing need for effective care strategies.

December 18, 2024

New BCMA-Directed Therapies Show Promise in Multiple Myeloma

Data presented at the American Society of Hematology (ASH) annual meeting highlighted advances in B-cell maturation antigen (BCMA)-directed therapies, including ABBV-383, a bispecific antibody with

December 24, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.